Skip to content

Study · Randomized controlled trial · n = 731 · 2025

8 results

Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.

Packer M, Zile MR, Kramer CM, Murakami M, Ou Y, Borlaug BA

Journal of the American College of Cardiology31 Mar 2025Cited by 27 (Europe PMC)

PMID40162940 (opens in a new tab)DOI10.1016/j.jacc.2025.03.009 (opens in a new tab)PepBankPUB-40162940
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and HFpEF, tirzepatide reduced the relative risk of major adverse heart failure events, and chronic kidney disease did not change this effect.

    In plain wordsIn adults with obesity and heart failure, tirzepatide lowered the risk of heart failure events versus placebo, with or without kidney disease.

    Peptide
    Tirzepatide
    Outcome
    DecreaseRelative risk of major adverse heart failure events
    Study

    n = 731

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · median 104 weeksAs given in this study (human).

    Source sentences

    Summary
    to reduce the relative risk of major adverse heart failure events and to improve KCCQ-CSS, quality of life, and functional capacity
    2 context sentences
    Summary · context
    The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD.
    Summary · context
    Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and HFpEF, tirzepatide improved the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and chronic kidney disease did not change this effect.

    In plain wordsIn adults with obesity and heart failure, tirzepatide improved a heart failure symptom score versus placebo, with or without kidney disease.

    Peptide
    Tirzepatide
    Outcome
    IncreaseKCCQ-CSS change
    Study

    n = 731

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    to reduce the relative risk of major adverse heart failure events and to improve KCCQ-CSS, quality of life, and functional capacity
    2 context sentences
    Summary · context
    The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD.
    Summary · context
    Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and HFpEF, tirzepatide improved quality of life, and chronic kidney disease did not change this effect.

    In plain wordsIn adults with obesity and heart failure, tirzepatide improved quality of life versus placebo, with or without kidney disease.

    Peptide
    Tirzepatide
    Outcome
    IncreaseQuality of life
    Study

    n = 731

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    to reduce the relative risk of major adverse heart failure events and to improve KCCQ-CSS, quality of life, and functional capacity
    2 context sentences
    Summary · context
    The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD.
    Summary · context
    Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and HFpEF, tirzepatide improved functional capacity, and chronic kidney disease did not change this effect.

    In plain wordsIn adults with obesity and heart failure, tirzepatide improved physical capacity versus placebo, with or without kidney disease.

    Peptide
    Tirzepatide
    Outcome
    IncreaseFunctional capacity
    Study

    n = 731

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    to reduce the relative risk of major adverse heart failure events and to improve KCCQ-CSS, quality of life, and functional capacity
    2 context sentences
    Summary · context
    The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD.
    Summary · context
    Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and HFpEF, chronic kidney disease did not influence the effect of tirzepatide on heart failure events or KCCQ-CSS, but the absolute risk reduction in primary events was numerically greater with CKD.

    In plain wordsIn adults with obesity and heart failure, kidney disease did not change how well tirzepatide worked. The absolute benefit was numerically greater with kidney disease.

    Peptide
    Tirzepatide
    Outcome
    No significant changeEffect modification by chronic kidney disease
    Study

    n = 731

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    CKD did not influence the effect of tirzepatide to reduce the relative risk of major adverse heart failure events and to improve KCCQ-CSS, quality of life, and functional capacity, but the absolute risk reduction in the primary events was numerically greater in patients with CKD.
    2 context sentences
    Summary · context
    The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD.
    Summary · context
    Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and HFpEF, tirzepatide increased eGFR at 52 weeks by both creatinine-based and cystatin C-based formulae, with considerable discordance in individual patients.

    In plain wordsIn adults with obesity and heart failure, tirzepatide raised kidney filtration estimates at 52 weeks, but the two methods differed in individual patients.

    Peptide
    Tirzepatide
    Outcome
    IncreaseeGFR at 52 weeks
    Study

    n = 731

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Furthermore, tirzepatide increased eGFR at 52 weeks, assessed by both creatinine-based and cystatin C-based formulae, but with considerable discordance in individual patients.
    2 context sentences
    Summary · context
    The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD.
    Summary · context
    Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and HFpEF, tirzepatide produced a decline in eGFR at 12 weeks with eGFR-creatinine but not with eGFR-cystatin C.

    In plain wordsIn adults with obesity and heart failure, tirzepatide lowered one kidney filtration estimate at 12 weeks, but not the other.

    Peptide
    Tirzepatide
    Outcome
    DecreaseeGFR at 12 weeks
    Study

    n = 731

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide produced a decline in eGFR at 12 weeks with eGFR-creatinine (but not eGFR-cystatin C)
    2 context sentences
    Summary · context
    The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD.
    Summary · context
    Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and HFpEF, tirzepatide improved eGFR at 52 weeks in all patients by cystatin C, but only in patients with CKD by creatinine.

    In plain wordsIn adults with obesity and heart failure, tirzepatide improved a kidney test at 52 weeks in all patients, and another only with kidney disease.

    Peptide
    Tirzepatide
    Outcome
    MixedeGFR improvement at 52 weeks by method and CKD status
    Study

    n = 731

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    it led to an improvement in eGFR at 52 weeks in all patients (when assessed by cystatin C), but only in patients with CKD (when assessed by eGFR-creatinine).
    2 context sentences
    Summary · context
    The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD.
    Summary · context
    Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04847557

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

Eli Lilly and Companyn = 73120 Apr 2021 to 2 Jul 2024

Obesity · Heart Failure With Preserved Ejection Fraction (HFpEF)

Trial pageClinicalTrials.govUpdated 20 Aug 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.